Cadisegliatin phase 3 adjunct to insulin
What this study tests
vTv Therapeutics phase 3 trial testing cadisegliatin, described by the sponsor as a liver-selective glucokinase activator, as an insulin adjunct to reduce level-2/3 hypoglycemia in adults with type 1 diabetes. Per the registry the trial is Active, not recruiting (enrollment closed); follow-up continues.
Editorial review: .
Registry checked: 2026-09-17. Registry’s own update: 2026-07-28.
Source dates appear in the references where available; this record has no dated citation metadata.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence at a glance
- Who can enter the study?
- Adults with type 1 diabetes. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
- Reported benefit and results
- No results posted. The registry now lists 150 participants and estimated primary completion in April 2027.Read the result sources and their limitations →
- Important harms
- Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
- Research access and approval
- Study regions: United States, Other regions. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
- What remains uncertain?
- Read the full discussion and original sources for study limitations. Planned endpoints and completion dates are not results.
Research status alone does not establish approval, clinical benefit or local availability.
Primary endpoints
- Change in incidence of level-2 or level-3 hypoglycemia
The full picture
This record has no longer discussion. Use the study criteria, reported results and original sources on this page to assess what is known and what remains unresolved.
Sources
- [1]NCT06334133: Cadisegliatin phase 3 adjunct to insulin · Trial registry — Registry checked 2026-08-08: ACTIVE_NOT_RECRUITING, estimated enrolment 150, primary completion April 2027, study completion May 2027; update posted 2026-07-28.